乌鸦传媒

Experts at ASH debate quadruplet therapy, dexamethasone modulation, and novel approaches

Study links strong relationships to better physical and emotional outcomes in myeloma care

Longer gaps between anti-BCMA agents associated with improved response rates, study finds

Phase III trial sparks discussion on defining and managing high-risk smoldering myeloma

DREAMM-7 findings help pave the way for Blenrep's return

Higher response rate, PFS, OS with cilta-cel, but ide-cel had lower rate of severe toxicity

Daratumumab significantly improved PFS, OS, but identity of high-risk population remains elusive

High-fiber diets tied to improved outcomes in stem-cell transplants, slowing myeloma precursors

A drug comeback, new FDA approvals, and a new standard for transplant-ineligible patients

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

High overall response rate, even though many were ineligible for trial leading to drug's approval